Research graph
References from Antitumor Activity and Prolonged Expression from a TRAIL-Expressing Adenoviral Vector. Local targets link to admitted publications; unresolved targets remain external evidence.
Apoptosis in cancer therapy: crossing the threshold
10.1016/0092-8674(94)90518-5 · 1994 · External reference
Identification and characterization of a new member of the TNF family that induces apoptosis
10.1016/1074-7613(95)90057-8 · 1995 · External reference
How TRAIL kills cancer cells, but not normal cells
10.1126/science.277.5327.768 · 1997 · External reference
Safety and antitumor activity of recombinant soluble Apo2 ligand
10.1172/jci6926 · 1999 · External reference
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
10.1038/5517 · 1999 · External reference
Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apoptosis in human malignant glioma cells
2001 · External reference
Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene
2001 · External reference
Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
10.1038/75045 · 2000 · External reference
Human brain-cell death induced by tumournecrosis factor inducing ligand (TRAIL)
10.1016/s0140-6736(00)02659-3 · 2000 · External reference
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
10.1038/86397 · 2001 · External reference
Direct stimulation of apoptotic signaling by soluble apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells
2001 · External reference
Viral vectortargeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA
1998 · External reference
Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth
10.1038/nm0497-437 · 1997 · External reference
A simplified system for generating recombinant adenoviruses
10.1073/pnas.95.5.2509 · 1998 · External reference
Immune parameters affecting adenoviral vector gene therapy in the brain
10.3109/13550289809114519 · 1998 · External reference
AP02 ligand: a novel lethal weapon against malignant glioma?
10.1016/s0014-5793(98)00409-8 · 1998 · External reference
In vitro expansion of a multipotent population of human neural progenitor cells
10.1006/exnr.1999.7098 · 1999 · External reference
Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
1999 · External reference
Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovrus-mediated gene therapy: implications for clinical trials
10.1038/15207 · 1999 · External reference
Fas ligand-induced apoptosis as a mechanism of immune privilege
10.1126/science.270.5239.1189 · 1995 · External reference
A role for CD95 ligand in preventing graft rejection
10.1038/377630a0 · 1995 · External reference
An antagonist decoy receptor and a death domain-containing receptor for TRAIL
10.1126/science.277.5327.815 · 1997 · External reference
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
10.1126/science.277.5327.818 · 1997 · External reference
Apoptosis control by death and decoy receptors
10.1016/s0955-0674(99)80034-9 · 1999 · External reference
Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily
10.1007/bf02592977 · 1996 · External reference
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
10.1074/jbc.271.22.12687 · 1996 · External reference
Tumor necrosis factor-related apoptosis-inducing ligand retains its apopto-sis-inducing capacity on Bcl-2-or Bcl-xL-overexpressing chemotherapy-resistant tumor cells
2000 · External reference
Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy
10.1073/pnas.030545097 · 2000 · External reference
Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy
10.1073/pnas.91.10.4407 · 1994 · External reference
Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo
10.4049/jimmunol.155.5.2564 · 1995 · External reference
"Stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions
10.4049/jimmunol.163.9.4886 · 1999 · External reference
Fas ligand-induced apoptosis
10.1146/annurev.genet.33.1.29 · 1999 · External reference
